HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Brod, S. A. Articles by Burns, D. K. Search for Related Content PubMed PubMed Citation Articles by Brod, S. A. Articles by Burns, D. K.

Suppression of relapsing experimental autoimmune encephalomyelitis in the SJL/J mouse by oral administration of type I interferons

Departments of Neurology (Dr. Brod) and Pathology (Dr. Burns), University of Texas Southwestern Medical Center a t Dallas, Dallas, TX.

We induced a chronic relapsing form of experimental autoimmune encephalomyelitis in 7- to 10-week-old female SJL/J mice using a subcutaneous injection of an emulsion containing syngeneic mouse spinal cord homogenate in phosphate-buffered saline and Mycobacterium tuberculosis (MT) in incomplete Freund's adjuvant. Following the animals' recovery from the first attack periods, we fed them varying doses of type I interferon (IFN) or mock IFN three times per week for 6 weeks. This treatment decreased proliferation to guinea pig myelin basic protein and MT compared with control in draining lymph node and diminished inflammation in the CNS. Oral IFN altered the cytokine profile of concanavalin A-activated spleen cells by decreasing IFN- secretion. These results suggest that type I IFNs are active by the oral route, have significant clinical and immunomodulatory effects, and can decrease an established and ongoing immune response to sensitized antigens. The oral administration of biologic-response modifiers, such as type I IFNs, provides a potentially nontoxic, convenient, continuous means of delivering immunoactive substances via the gut regional immune system that can alter cytokine production and suppress clinical relapses.

Address correspondence and reprint requests to Dr. Staley A. Brod, Department of Neurology 7.044, University of Texas Health Science Center at Houston, P.O. Box 20708, Houston, TX 77225.

Supported in part by a grant from the National Multiple Sclerosis Society.

Received August 5, 1993. Accepted for publication in final form December 10, 1993.

This article has been cited by other articles:

				C Polman, F Barkhof, L Kappos, C Pozzilli, R Sandbrink, F Dahlke, P Jakobs, A Lorenz, and European Oral Interferon Beta-1a in Relapsing-Remi Oral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study Multiple Sclerosis, August 1, 2003; 9(4): 342 - 348. [Abstract] [PDF]

				A. J. Slavin, R. Maron, and H. L. Weiner Mucosal administration of IL-10 enhances oral tolerance in autoimmune encephalomyelitis and diabetes Int. Immunol., June 1, 2001; 13(6): 825 - 833. [Abstract] [Full Text] [PDF]

				M.-N. Kweon, K. Fujihashi, J. L. VanCott, K. Higuchi, M. Yamamoto, J. R. McGhee, and H. Kiyono Lack of Orally Induced Systemic Unresponsiveness in IFN-{gamma} Knockout Mice J. Immunol., February 15, 1998; 160(4): 1687 - 1693. [Abstract] [Full Text] [PDF]